Passage Bio Announces Third Gene Therapy Development Program in Krabbe Disease and Supports Million Dreams Fundraising Gala

PHILADELPHIA, May 30, 2019 (GLOBE NEWSWIRE) — Passage Bio, a genetic medicines company developing AAV-delivered gene therapies for the treatment of rare monogenic central nervous systemThe central nervous system (CNS) is made up of the brain and the spinal cord. diseases, today announced that its third clinical trialA clinical trial is research designed to understand the safety and efficacy of a drug, biologic or device.  There are 4 phases to most clinical trials from Phase 1 that seeks to answer safety concern program will be for infantile Krabbe disease, an inheritedThe way genes are passed down from one generation to the next.  There are many different types of inheritance patterns.  Krabbe disease is inherited in an autosomal recessive pattern of inheritance. disease that causes progressive damage to the nervous systemThe nervous system of the body is made up of the Central Nervous System (CNS) and the Peripheral Nervous System (PNS)..

Link to Full Release